The Asia Pacific Digital Dose Inhaler Market should witness market growth of 20.7% CAGR during the forecast period (2023-2030).
Using digital dose inhalers can alleviate the difficulties that patients and medical professionals face when treating respiratory disorders. Due to their interconnected digital capabilities, smart inhalers and mobile applications work together to monitor medication administration schedules and subsequent doses. Digital dose inhalers can deliver track adherence and dosage reminders, accurately record the date, time, and location of every dose administered, and offer Bluetooth access to readily shareable data.
Patients may medicate themselves while using a digital dose inhaler by swiftly inhaling an aerosolized medicine into their lungs in line with a predetermined dose. The market is seeing a rapid expansion of inhalation therapy devices, including meters that inhalers integrated with an e-dose counter, internet-connected and compact inhalers, and others.
Asia is the largest and most populous continent in the globe. Asia's most prevalent chronic disease is asthma. In Asia, the prevalence of pediatric asthma has steadily increased over the past five decades [5]. The activity of asthma research in Asian countries has multiplied over the past decade, a reflection of the disease's growing significance. COPD is a significant health concern and a leading cause of chronic morbidity and mortality. The prevalence of COPD continues to rise in Asian nations. These increases are primarily attributable to the tobacco pandemic and interior and outdoor air pollution in Asian nations. In terms of the total number of fatalities and the burden of disease, determined in years of life lost and years spent living with disability, the burden of COPD in Asia is presently greater than in developed Western countries. This rising incidence of COPD and asthma in the nation is anticipated to contribute to expanding the regional market.
The China market dominated the Asia Pacific Digital Dose Inhaler Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3,222.4 million by 2030. The Japan market is registering a CAGR of 19.8% during (2023-2030). Additionally, The India market would showcase a CAGR of 21.2% during (2023-2030).
Based on Product, the market is segmented into Metered Dose Inhaler (MDI), and Dry Powder Inhaler (DPI). Based on Type, the market is segmented into Branded Medication, and Generic Medication. Based on Indication, the market is segmented into COPD, Asthma, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sensirion AG, Teva Pharmaceuticals Industries Ltd., OPKO Health, Inc., Propeller Health (ResMed, Inc.), Novartis AG, AstraZeneca PLC, Glenmark Pharmaceuticals Limited, Beximco Pharmaceuticals Ltd., GlaxoSmithKline PLC and Mundipharma Deutschland GmbH & Co. KG.
Using digital dose inhalers can alleviate the difficulties that patients and medical professionals face when treating respiratory disorders. Due to their interconnected digital capabilities, smart inhalers and mobile applications work together to monitor medication administration schedules and subsequent doses. Digital dose inhalers can deliver track adherence and dosage reminders, accurately record the date, time, and location of every dose administered, and offer Bluetooth access to readily shareable data.
Patients may medicate themselves while using a digital dose inhaler by swiftly inhaling an aerosolized medicine into their lungs in line with a predetermined dose. The market is seeing a rapid expansion of inhalation therapy devices, including meters that inhalers integrated with an e-dose counter, internet-connected and compact inhalers, and others.
Asia is the largest and most populous continent in the globe. Asia's most prevalent chronic disease is asthma. In Asia, the prevalence of pediatric asthma has steadily increased over the past five decades [5]. The activity of asthma research in Asian countries has multiplied over the past decade, a reflection of the disease's growing significance. COPD is a significant health concern and a leading cause of chronic morbidity and mortality. The prevalence of COPD continues to rise in Asian nations. These increases are primarily attributable to the tobacco pandemic and interior and outdoor air pollution in Asian nations. In terms of the total number of fatalities and the burden of disease, determined in years of life lost and years spent living with disability, the burden of COPD in Asia is presently greater than in developed Western countries. This rising incidence of COPD and asthma in the nation is anticipated to contribute to expanding the regional market.
The China market dominated the Asia Pacific Digital Dose Inhaler Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3,222.4 million by 2030. The Japan market is registering a CAGR of 19.8% during (2023-2030). Additionally, The India market would showcase a CAGR of 21.2% during (2023-2030).
Based on Product, the market is segmented into Metered Dose Inhaler (MDI), and Dry Powder Inhaler (DPI). Based on Type, the market is segmented into Branded Medication, and Generic Medication. Based on Indication, the market is segmented into COPD, Asthma, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sensirion AG, Teva Pharmaceuticals Industries Ltd., OPKO Health, Inc., Propeller Health (ResMed, Inc.), Novartis AG, AstraZeneca PLC, Glenmark Pharmaceuticals Limited, Beximco Pharmaceuticals Ltd., GlaxoSmithKline PLC and Mundipharma Deutschland GmbH & Co. KG.
Scope of the Study
By Product
- Metered Dose Inhaler (MDI)
- Dry Powder Inhaler (DPI)
By Type
- Branded Medication
- Generic Medication
By Indication
- COPD
- Asthma
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Sensirion AG
- Teva Pharmaceuticals Industries Ltd.
- OPKO Health, Inc.
- Propeller Health (ResMed, Inc.)
- Novartis AG
- AstraZeneca PLC
- Glenmark Pharmaceuticals Limited
- Beximco Pharmaceuticals Ltd.
- GlaxoSmithKline PLC
- Mundipharma Deutschland GmbH & Co. KG
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Asia Pacific Digital Dose Inhaler Market by Product
Chapter 6. Asia Pacific Digital Dose Inhaler Market by Type
Chapter 7. Asia Pacific Digital Dose Inhaler Market by Indication
Chapter 8. Asia Pacific Digital Dose Inhaler Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Sensirion AG
- Teva Pharmaceuticals Industries Ltd.
- OPKO Health, Inc.
- Propeller Health (ResMed, Inc.)
- Novartis AG
- AstraZeneca PLC
- Glenmark Pharmaceuticals Limited
- Beximco Pharmaceuticals Ltd.
- GlaxoSmithKline PLC
- Mundipharma Deutschland GmbH & Co. KG
Methodology
LOADING...
